Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Working Capital Changes (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Other Working Capital Changes for 6 consecutive years, with -$1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes changed N/A year-over-year to -$1.7 million, compared with a TTM value of -$1.9 million through Sep 2025, down 115.85%, and an annual FY2024 reading of -$899000.0, down 164.91% over the prior year.
  • Other Working Capital Changes was -$1.7 million for Q3 2025 at Ovid Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $3.8 million in Q2 2023 and bottomed at -$12.4 million in Q1 2021.
  • Average Other Working Capital Changes over 5 years is -$866671.4, with a median of -$265513.0 recorded in 2022.
  • The sharpest move saw Other Working Capital Changes plummeted 14364.4% in 2021, then skyrocketed 661.99% in 2023.
  • Year by year, Other Working Capital Changes stood at -$12.4 million in 2021, then surged by 97.86% to -$265513.0 in 2022, then crashed by 230.3% to -$877000.0 in 2023, then decreased by 2.51% to -$899000.0 in 2024, then crashed by 90.43% to -$1.7 million in 2025.
  • Business Quant data shows Other Working Capital Changes for OVID at -$1.7 million in Q3 2025, $1.0 million in Q2 2025, and -$325000.0 in Q1 2025.